

# A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)

NCT07290062

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 1
<b>Sponsor</b>	Insmed Gene Therapy LLC
<b>Enrollment</b>	23 participants

## Key Eligibility Criteria

---

### Inclusion (7)

- Participant with body mass index (BMI)  $\geq 18$  kilograms per square meter ( $\text{kg}/\text{m}^2$ ).
  - Participant with symptomatic ALS as diagnosed by Gold Coast diagnostic criteria.
  - Sporadic ALS cohorts: Negative testing for known monogenic mutations associated with familial ALS.
  - SOD1-ALS (Cohorts 2 and 3 only): Confirmed pathogenic SOD1 mutation, with negative testing for other genetic mutations associated with familial ALS.
  - Any polymorphism or mutation in the coding region will require additional review by the Sponsor to determine compatibility with the study intervention.
- ... and 2 more (see full listing online)

### Exclusion (2)

- Previous treatment for ALS with cellular or gene therapies.
- Any investigational medication or treatment (for ALS or other condition).

## Locations (3 total)

---

USA001, Columbia, Missouri, United States  
USA007, Columbus, Ohio, United States  
USA006, Philadelphia, Pennsylvania, United States